BTK inhibitors: past, present, and future
Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for B
cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor …
cell lymphomas such as chronic lymphocytic leukemia (CLL). The first-in-class BTK inhibitor …
Advances in the treatment of relapsed/refractory marginal zone lymphoma
H Wang, X Wan, Y Zhang, J Guo, O Bai - Frontiers in Oncology, 2024 - frontiersin.org
Marginal zone lymphoma (MZL) is the second most common subtype of inert B-cell non-
Hodgkin's lymphoma, accounting for 5–15% of non-Hodgkin's lymphoma cases. Patients …
Hodgkin's lymphoma, accounting for 5–15% of non-Hodgkin's lymphoma cases. Patients …
Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis
CA Dasanu, SK Mann, M Baidya, XP Mdluli… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Randomized clinical trials (RCTs) have suggested that BTK
inhibitors (BTKis) might increase infectious disease (ID) risk. Systematic analysis on this …
inhibitors (BTKis) might increase infectious disease (ID) risk. Systematic analysis on this …
[HTML][HTML] Translational Insights into the Genetics and Immunobiology of Relapsed/Refractory Follicular Lymphoma
B Yaniv, B Tanenbaum, V Kazakova, SA Patel - Leukemia Research, 2024 - Elsevier
Although follicular lymphoma (FL) is traditionally classified as an indolent subtype of B cell
non-Hodgkin lymphoma, clinical trajectories are often diverse based on unique disease …
non-Hodgkin lymphoma, clinical trajectories are often diverse based on unique disease …
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial
A Tedeschi, CS Tam, RG Owen, C Buske… - Future …, 2024 - Taylor & Francis
Aim ASPEN is a randomized, open-label, Phase III study comparing zanubrutinib and
ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods …
ibrutinib in patients with Waldenström macroglobulinemia (WM). Materials & methods …
BTKi treatment in MZL
K Bouabdallah - Hématologie, 2024 - jle.com
Les lymphomes de la zone marginale sont un groupe hétérogène d'hémopathies
lymphoïdes B peu fréquentes et généralement indolentes. Le récepteur des lymphocytes B …
lymphoïdes B peu fréquentes et généralement indolentes. Le récepteur des lymphocytes B …
Place des inhibiteurs de la tyrosine kinase de Bruton dans le lymphome de la zone marginale.
K Bouabdallah - Hematologie, 2024 - search.ebscohost.com
Les lymphomes de la zone marginale sont un groupe hétérogène d'hémopathies
lymphoïdes B peu fréquentes et généralement indolentes. Le récepteur des lymphocytes B …
lymphoïdes B peu fréquentes et généralement indolentes. Le récepteur des lymphocytes B …
[引用][C] New Agents in Marginal Zone Lymphoma
IS Lossos - Clinical lymphoma, myeloma and leukemia, 2024 - scholarship.miami.edu
Abstract acalabrutinib antibody-drug conjugates bispecific antibodies BTK inhibitors
Extranodal marginal zone lymphoma ibrutunib nodal marginal zone lymphoma splenic …
Extranodal marginal zone lymphoma ibrutunib nodal marginal zone lymphoma splenic …